buformin has been researched along with Shock, Cardiogenic in 1 studies
Buformin: An oral hypoglycemic agent that inhibits gluconeogenesis, increases glycolysis, and decreases glucose oxidation.
buformin : A member of the class of biguanides that is biguanide substituted by a butyl group at position 1. It is an antidiabetic drug with potential antitumor effect.
Shock, Cardiogenic: Shock resulting from diminution of cardiac output in heart disease.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Berger, W | 1 |
| Mehnert-Aner, S | 1 |
| Mülly, K | 1 |
| Heierli, C | 1 |
| Ritz, R | 1 |
1 other study available for buformin and Shock, Cardiogenic
| Article | Year |
|---|---|
[10 cases of lactic acidosis during biguanide therapy (buformin and phenformin)].
Topics: Acidosis; Biguanides; Buformin; Diabetes Mellitus; Glucagon; Humans; Lactates; Liver; Metformin; Phe | 1976 |